Why is Otsuka’s Simtriyo FDA approval important for the ADHD market?

FDA approved Otsuka’s ADHD drug Simtriyo, which FiercePharma described as a first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor. The approval gives Otsuka what Jefferies called its next major CNS launch and positions Simtriyo as a potential blockbuster in a large, under-penetrated ADHD market.